Aprutumab, {a specific therapeutic, represents {a significant step forward in combating cancers characterized by FGFR2 fusions. This targeted treatment functions by specifically binding to FGFR2, a tyrosine kinase https://aprutumab-monoclonal-ant967724.activoblog.com/profile